Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 9/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23602185 | 0.90 | ADRB2 (0.42) | ADRB2ADRB1GLSGBA1 | |
| SCHEMBL23807086 | 0.89 | GBA1 (0.43) | ADRB2ADRB1GBA1 | |
| SCHEMBL21106552 | 0.89 | ADRB2 (0.44) | ADRB2ADRB1GLSGBA1 | |
| SCHEMBL22861721 | 0.89 | GLS (0.46) | ADRB2ADRB1GLSGBA1 | |
| SCHEMBL23696408 | 0.86 | ADRB2 (0.40) | ADRB2ADRB1GLSGBA1 | |
| SCHEMBL22525949 | 0.86 | GBA1 (0.43) | ADRB2ADRB1GBA1 | |
| SCHEMBL22802142 | 0.85 | NOTUM (0.44) | NOTUMGLSGBA1 | |
| SCHEMBL23518630 | 0.83 | GBA1 (0.43) | NOTUMGLSGBA1 | |
| SCHEMBL24812463 | 0.82 | GBA1 (0.53) | NOTUMGLSGBA1 | |
| SCHEMBL22837782 | 0.81 | GBA1 (0.42) | ADRB2ADRB1GLSGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ADRB2 4578/4885ADRB1 4186/4885NOTUM 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.